drugset / Trial / NCT02979821
Poziotinib in Stage IV Lung Adenocarcinoma With HER2 Mutation (KASTT001)
Phase 2
Completed
6 enrolled
Korean Association for the Study of Targeted Therapy
Chonnam National University Hospital · collabChungnam National University Hospital · collabKonkuk University Medical Center · collabKosin University Gospel Hospital · collabKyungpook National University Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
In this trial, treatment efficacy and safety of Poziotinib will be assessed in patients with stage IV lung adenocarcinoma harboring HER2 mutation.
Timeline
- Start
- 2016-10
- Primary completion
- 2017-12
- Completion
- 2017-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Poziotinib | Small molecule | 12 mg | Oral |